| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Nabla Bio partners with Takeda to use its AI platform JAM for designing antibodies, receiving upfront payments and potential su...
Johnson & Johnson is in talks to buy Protagonist Therapeutics in a deal that could expand its immunology and cancer drug po...
Galecto stock spiked on heavy trading with no clear news, while the company highlights funding plans, pipeline updates, and cli...
– Takeda is the Leader in Orexin Science and is on Track to Submit Global Regulatory Applications Starting in Fiscal Year 2025–...
Takeda announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (...
